# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹581.7 Cr** consolidated (+13% YoY) * EBITDA: ₹68.9 Cr consolidated (11.8% margin) * **Core B2B EBITDA:** **₹72 Cr** (~14% margin) * **ROCE:** **13%** (~post-tax WACC) * **Divestment Proceeds (Expected):** **₹150 Cr** from partial consumer business sale ## B. Revenue Growth * **Resilient Top-Line Performance:** 13% YoY growth achieved in Q3 FY26 despite weak domestic demand, driven by **strong volume momentum** and broad-based segment execution. * **Volume as Primary Growth Engine:** Volume contributed **10%-12%** to growth, with pricing largely neutral due to offsetting segmental movements; trend expected to persist through 9MFY26. ## C. EBITDA & Margins * **Margin Pressure from Strategic Investments:** Consolidated EBITDA margin at 8% reflects deliberate reinvestment in capacity, product innovation, market seeding, and higher employee costs from new labor codes. * **Core B2B Profitability Near Normal Range:** Excluding underperforming institutional and B2C segments, core B2B EBITDA margin of ~14% remains slightly below historical 15%-16%, signaling ongoing optimization efforts. * **Structural Margin Erosion Persists:** Despite lower raw material costs, per-kg margin pressure has driven profitability down from 18% at IPO to sub-12%, highlighting operational and mix challenges. ## D. Balance Sheet * **Stable Earnings, Limited ROCE Upside:** Quarterly PAT has stabilized at ₹30 Cr, but ROCE of 13%—only in line with post-tax WACC—suggests limited value creation beyond current levels without structural change. * **Strategic Divestment to Unlock Capital:** Plan to exit capital-intensive consumer businesses for ~₹150 Cr aims to reduce marketing overhead and redirect resources toward higher-return segments. --- # 2. Segment & Product Performance ## A. Key Figures * **HPPC Growth:** **11%** YoY * **Textile Specialty Chemicals Growth:** **18%** YoY * **Animal Health and Nutrition Growth:** **39%** YoY ## B. HPPC Growth * **Broad-Based Resilience:** HPPC delivered solid growth across all segments despite a weak domestic environment, underpinned by diversified exposure and strong customer relationships. * **Regional Divergence:** European operations face headwinds from low sentiment and export softness, offset by robust performance in MENA, the Middle East, and Turkey. * **Institutional & B2C Challenges:** These verticals remain under pressure but show signs of stabilization due to improved product mix and cost discipline; unprofitable offerings under strategic review. ## C. Textile Chemicals * **Strong Dual-Market Expansion:** Textile segment achieved robust growth on the back of solid domestic recovery and export gains, including new customer wins in Turkey, Uzbekistan, and Morocco. * **Demand Rebound with Caveats:** Domestic offtake improved notably in Surat and Ludhiana, though large end customers like Welspun and Indo Count saw volume declines due to tariff-related pressures. * **Sustained Momentum Expected:** Recent demand surge is viewed as structural rather than transitory, signaling continued strength in the near term. ## D. Animal Health * **Outstanding Segment Performance:** Animal Health and Nutrition posted exceptional growth, driven by strong demand and seasonal tailwinds in the second half. * **Export Capacity Buildout:** Bangladesh export ramp-up supported by new trace mineral and vitamin premix plant coming online this quarter, set to enhance scale. * **B2C Under Strategic Review:** Underperforming B2C vertical being reevaluated for potential restructuring or exit to reduce losses in coming quarters. --- # 3. Capacity & Utilization ## A. Key Figures * Dahej & Unitop Ramp-up Timeline: Full utilization expected over 2 years, with operating leverage and 90% capacity utilization by end of FY27 * **Unitop Capacity:** **15,000 MTPA** Ethoxylation facility; current utilization at **10–15%** * **KSA Initial Funding:** **$8 million** approved as initial equity infusion; total CAPEX to be determined ## B. Dahej Ramp-up * **Phased Expansion on Track:** First phase of Ethoxylation capacity commissioned and ramping; balance capacity expected online within current quarter, with second phase in Q4. * **Margin Recovery Path:** Recent and upcoming capacity additions set to improve margin profile, supported by operating leverage materializing through 2027. ## C. Unitop Facility * **Steady Ramp-up Amid Supply Constraints:** New 15,000 MTPA facility ramping steadily despite near-term Ethylene Oxide shortages, expected to ease in current calendar year. * **Long-Term Utilization Target:** Optimal utilization targeted over two years, with **90% utilization expected by end of FY27**. * **Global Expansion Footprint:** Small formulation plant in Thailand to commence operations by end of Q4 or early Q1, initially serving textile segment with future expansion into AHN and HPPC. ## D. KSA Greenfield * **Strategic Greenfield Entry:** In-principle Board approval granted for KSA specialty chemicals facility to enhance supply resilience, speed-to-market, and global footprint. * **KSA Strategic Advantages:** Selected for **~35% lower raw material costs**, proximity to Europe/Africa/MENA, and strong petrochemical infrastructure; long-term supply contracts underpinned by favorable pricing formula. * **Execution Model De-risks Ramp-up:** Facility to mirror proven Indian operations, leveraging existing technology and product expertise; dedicated KSA-based team to be established. * **Initial Steps Underway:** Land acquisition, raw material assessment, and cost evaluation in progress; $8 million equity infusion for groundwork, with full CAPEX pending formal approval. --- # 4. Export & Geography Mix ## A. Key Figures * **International Growth:** **26% YoY** in 9M FY26 (vs. domestic +10%) * **Export Contribution:** **33% of turnover** in Q3 · **30%** in 9M FY26 ## B. International Growth * **Strong Export Momentum:** Robust year-on-year growth in exports driven by expanded customer base, deeper relationships, and rising wallet share with strategic partners, significantly outpacing domestic performance. * **Geographic Diversification:** Global footprint broadened into **Philippines, Indonesia, Nepal, Bangladesh, Egypt, Nigeria, Thailand, and South America**, with active product registration efforts in Southeast Asia and Central Europe. * **Strategic Expansion Rationale:** Overseas manufacturing in KSA is part of a long-term plan to access MNC customers and unlock cross-selling, not a reaction to tariffs or India export constraints, with planning initiated well before recent policy changes. * **KSA as Growth Catalyst:** KSA facility offers strategic proximity to Europe, MENA, and Africa, enabling faster delivery and stronger positioning in oil and gas; expected to accelerate international growth and meet regional demand for value-added specialties. ## C. GCC Engagement * **Deepening GCC Ties:** Active demand mapping and advance supply discussions with **at least two KSA/GCC-based customers**, signaling strong early commercial traction ahead of facility operations. * **Operational Edge:** Expansion provides greater flexibility and scalability than Indian export model, addressing geographic and logistical limitations despite India’s strong export track record over the past 2–5 years. ## D. New Markets * **Textile Export Surge:** Vietnam and Bangladesh teams established to support textile business, contributing to **significant growth in textile exports** this quarter. * **Growth Sustainability:** Focus on new market entry and product innovation to maintain export momentum, especially in high-potential segments like textiles. --- # 5. R&D & Product Innovation ## A. Key Figures * **New Product Sales:** **>20%** of total sales ## B. New Product Sales * **R&D-Driven Growth Inflection:** More than 20% of sales now derived from new R&D-developed products, signaling a shift toward innovation-led, higher-margin revenue streams. * **Strategic CAPEX Pivot:** Capacity expansion largely complete; focus shifts to **optimal asset utilization** and accelerating new product development and piloting. * **Enhanced Innovation Engine:** Significant R&D capability build-out through targeted senior hires and investments, with near-term product launches anticipated. ## C. Bio-surfactant Milestone * **Commercial Validation Achieved:** Fermentation and bio-surfactant facilities secured approval from **world’s leading personal care company**, unlocking access to premium global markets. * **Multinational Traction:** Positive engagement from **two large multinational corporations** indicates strong commercial potential and scalability of bio-surfactant platform. --- # 6. Risks & Supply Constraints ## A. EO Supply Delay * **Operational Flexibility:** Leveraging reactor fungibility to scale non-Ethylene Oxide product lines, maintaining throughput and asset utilization amid supply constraints. ## B. Management Bandwidth * **Strategic Focus:** Expansion into KSA recognized as a stretch on management bandwidth; priority remains on monetizing existing investments and developments in India. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Margin Guidance:** **12%–13%** for remainder of FY25 and FY26 (pending EO supply resolution) · **~15%** targeted post-consumer business exit * **Capex Outlook:** **₹200 Cr** total capitalized CAPEX expected by end-FY26 ## B. Margin Recovery * **Profitability Roadmap:** Strategic pivot to higher-margin products and exit from low-return consumer segments to drive margin recovery toward **15%**. * **Near-Term Margin View:** Margins to stabilize in 12%–13% range pending resolution of **EO supply constraints**, expected by Q3. * **Growth & Seasonality:** Q3 seasonally weaker, but export performance expected to improve; Q4 to see average growth with strong export momentum. ## C. Capex Completion * **Capex Trajectory:** Full-year group CAPEX on track for ₹200 Cr by FY26; specific allocations pending final evaluation. * **EBITDA Outlook:** Management anticipates **healthy growth in EBITDA** both in absolute terms and margin, driven by operational improvements and mix shift.